Singulair and Viral uveitis - a phase IV clinical study of FDA data

Summary:

Viral uveitis is reported as a side effect among people who take Singulair (montelukast sodium), especially for people who are female, 40-49 old, also take Zantac, and have Urticaria.

The phase IV clinical study analyzes which people have Viral uveitis when taking Singulair. It is created by eHealthMe based on reports of 125,532 people who have side effects when taking Singulair from the FDA, and is updated regularly.

What is Singulair?

Singulair has active ingredients of montelukast sodium. It is often used in asthma. eHealthMe is studying from 129,752 Singulair users. Check the latest studies of Singulair.

What is Viral uveitis?

Viral uveitis (inflammation at any point of the uveal track) is found to be associated with 12 drugs and 29 conditions by eHealthMe. Check the latest studies of Viral uveitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 23, 2026

125,532 people reported to have side effects when taking Singulair.
Among them, 11 people (0.01%) have Viral uveitis.

Among these 11 people:

What is the gender of people who have Viral uveitis when taking Singulair? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Viral uveitis when taking Singulair? *

What are other drugs people take besides Singulair? *

What are other side effects people have besides Viral uveitis? *

Weight Decreased: 10 people, 90.91%
Muscle Spasms (muscle contraction): 10 people, 90.91%
Diarrhea: 10 people, 90.91%
Drug Intolerance (drug sensitivity): 10 people, 90.91%
Food Allergy: 10 people, 90.91%
Hypersensitivity: 10 people, 90.91%
Itching: 10 people, 90.91%
Urticaria (rash of round, red welts on the skin that itch intensely): 10 people, 90.91%
Aphonia (inability to produce voice): 10 people, 90.91%
Nonspecific Reaction (unspecified reaction): 10 people, 90.91%

What are the existing conditions these people have? *

Urticaria (rash of round, red welts on the skin that itch intensely): 10 people, 90.91%
Immunodeficiency Common Variable: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Singulair and have Viral uveitis?

- Check whether Viral uveitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Singulair:

Singulair (129,752 reports)

Viral uveitis treatments and more:

Viral uveitis (114 reports)

Browse all side effects of Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Viral uveitis:

Viral uveitis (12 drugs)

Browse all the conditions that are associated with Viral uveitis:

Viral uveitis (29 conditions)

Related publications that referenced our studies

Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK, "A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis", Journal of Young Pharmacists, 2013 Jun .
Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK, "A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis", Journal of Young Pharmacists, 2013 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on montelukast sodium (the active ingredients of Singulair) and Singulair (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.